Evidence map›Paper›PMID 27427762›Full record

ArticlePloS one2016

Neutralizing Antibodies against Plasmodium falciparum Associated with Successful Cure after Drug Therapy.

Yun Shan Goh, Kaitian Peng, Wan Ni Chia, Anthony Siau, Kesinee Chotivanich, Anne-Charlotte Gruner, Peter Preiser, Mayfong Mayxay, Sasithon Pukrittayakamee, Kanlaya Sriprawat and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Vaccines · 2021
    Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 4 countries.

Yun Shan GohSingapore Immunology Network, Agency for Science, Technology and Research, Singapore, Singapore.
Kaitian PengSingapore Immunology Network, Agency for Science, Technology and Research, Singapore, Singapore.
Wan Ni ChiaSingapore Immunology Network, Agency for Science, Technology and Research, Singapore, Singapore.
Anthony SiauSchool of Biological Sciences, Nanyang Technological University, Singapore, Singapore.
Kesinee ChotivanichFaculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Anne-Charlotte GrunerSingapore Immunology Network, Agency for Science, Technology and Research, Singapore, Singapore.
Peter PreiserSchool of Biological Sciences, Nanyang Technological University, Singapore, Singapore.
Mayfong MayxayLao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Mahosot Hospital, Vientiane, Laos.
Sasithon PukrittayakameeFaculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Kanlaya SriprawatShoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand.
Francois NostenShoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand.
Nicholas J WhiteCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Laurent ReniaSingapore Immunology Network, Agency for Science, Technology and Research, Singapore, Singapore.ORCID http://orcid.org/0000-0003-0349-1557
Agency for Science, Technology and Research · SGMahidol University · THNanyang Technological University · SGMahosot Hospital · LA

Funding

Wellcome Trust
6 · The paper itself

Abstract

An effective antibody response can assist drug treatment to contribute to better parasite clearance in malaria patients. To examine this, sera were obtained from two groups of adult patients with acute falciparum malaria, prior to drug treatment: patients who (1) have subsequent recrudescent infection, or (2) were cured by Day 28 following treatment. Using a Plasmodium falciparum antigen library, we examined the antibody specificities in these sera. While the antibody repertoire of both sera groups was extremely broad and varied, there was a differential antibody profile between the two groups of sera. The proportion of cured patients with antibodies against EXP1, MSP3, GLURP, RAMA, SEA and EBA181 was higher than the proportion of patients with recrudescent infection. The presence of these antibodies was associated with higher odds of treatment cure. Sera containing all six antibodies impaired the invasion of P. falciparum clinical isolates into erythrocytes. These results suggest that antibodies specific against EXP1, MSP3, GLURP, RAMA, SEA and EBA181 in P. falciparum infections could assist anti-malarial drug treatment and contribute to the resolution of the malarial infection.

Indexed as

Immunity, HumoralAcute DiseaseAdolescentAdultAntibodies, NeutralizingAntibodies, ProtozoanAntibody SpecificityAntigens, ProtozoanAntimalarialsArtemetherArtemisininsAzithromycinCohort StudiesErythrocytesEthanolaminesFemaleAntibodies, NeutralizingAntibodies, ProtozoanAntigens, ProtozoanAntimalarialsArtemetherArtemisininsAzithromycinEBA-181 protein, Plasmodium falciparumEthanolaminesFluorenesglutamate-rich protein, PlasmodiumImmune SeraLumefantrinemerozoite surface protein 3, PlasmodiumProtozoan ProteinsQF116 antigen, Plasmodium falciparum

Identifiers

PMID27427762
PMCPMC4948787
OpenAlexW2506659675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.